Highlighted Clinical Investigators
Highlighted Investigators
Dr. Mohammed M. Moursi
Dr. Barry F. Uretsky
Credentials
University of Arkansas for Medical Sciences,
Little Rock, Arkansas
Chief, Vascular Surgery
Central Arkansas Veteran’s Healthcare System,
Little Rock, Arkansas
University of Arkansas for Medical Sciences,
Little Rock, Arkansas
Director, Interventional Cardiology
Central Arkansas Veteran’s Healthcare System,
Little Rock, Arkansas
Selected Completed/Ongoing Clinical Trials
and effectiveness of the Trivascular AAA
stent-graft system.
Saxagliptin assessment of vascular outcomes
recorded in patients with diabetes mellitus.
A randomized double blind parallel group multi-
center Phase IIIb study to compare
Ticagrelor with Clopidogrel treatment on the
risk of cardiovascular death, myocardial infarction
and ischemic stroke in patients with established
peripheral artery disease.
MarrowStim PAD kit for the treatment of critical
limb ischemia in subjects with severe peripheral
arterial disease.
Occlusive/stenotic peripheral artery
revascularization study; A multi-center clinical
trial of the Misago self-expanding stent system
for superficial femoral artery.
placebo in subjects following acute coronary
syndrome to compare incidence of major adverse
cardiovascular events.
A prospective randomzied multi-center double
blind trial to assess the effectiveness and safety of
different durations of dual anti-platelet therapy
(DAPT) in subjects undergoing percutaneous
coronary intervention with the Cypher stent.
A prospective multi-center randomized double
blind trial to assess the effectiveness and safety of
12 versus 30 months of dual anti-platelet therapy in
subjects undergoing percutaneous coronary
intervention with either drug-eluting stent or bare
metal stent placement for the treatment of
coronary artery lesions.
A randomized double blind placebo controlled
parallel group multinational trial to assess the
prevention of thrombotic events with Ticagrelor
compared to placebo on a background of acetly
acid therapy in patients with history of myocardial
infarction.
Quadripolar CRT-D on currently approved lead
systems – CROSS X4 Study.